Farasat et al made some interesting observations regarding the use of β blockade in heart failure with a preserved ejection fraction, particularly with regard to women. Their findings are somewhat at odds with the findings of the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure (SENIORS) substudy, which found that nebivolol was equally effective at reducing all-cause mortality and cardiovascular hospitalization in patients with impaired (ejection fraction ≤35%) and relatively preserved (ejection fraction >35%) systolic function. A possible reason for this is apparent in the differing demographics between men and women in Farasat et al’s study. A significantly larger proportion of women discharged on β blockers were in rhythms other than sinus at the time of admission. The precise natures of the arrhythmias are not elaborated on, but it would be reasonable to infer that it was arrhythmia that drove the nonrandomized use of β blockers in this group and the failure of therapy to control this arrhythmia that resulted in readmission, not β blockade or gender.